MRE-269CAS号： 475085-57-5分子式： C25H29N3O3分子量： 419.52描述纯度储存/保存方法别名外观可溶性/溶解性靶点In vitro(体外研究)In vivo(体内研究)
| 产品描述 | |
| 描述 |
MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist.
|
| 纯度 |
98%
|
| 储存/保存方法 |
Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
|
| 基本信息 | |
| 别名 |
ACT-333679
|
| 外观 |
Off-White to Light Yellow Solid
|
| 可溶性/溶解性 |
DMSO : 50 mg/mL (119.18 mM; Need ultrasonic)
|
| 生物活性 | |
| 靶点 |
Prostaglandin Receptor
|
| In vitro(体外研究) |
MRE-269 induces endothelium-independent vasodilation of rat extralobar pulmonary artery (EPA). MRE-269 or other IP receptor agonists including epoprostenol, iloprost, treprostinil and beraprost increase cAMP levels in hPASMC. MRE-269 induces concentration-dependent vasodilation in LPA(+), LPA(-), and SPA(-).
|
| In vivo(体内研究) |
The vasorelaxant effects of MRE-269 on rat small intralobar pulmonary artery (SIPA) and EPA are the same, while the other IP receptor agonists induce less vasodilation in SIPA than in EPA. MRE-269 produces substantial relaxation of rat small pulmonary artery, although its effects are only significant at high concentrations of above 10 μM (pEC50, 4.98±0.22). By contrast, in rat small pulmonary veins, MRE-269 only produces minimal relaxation over the whole concentration range, with only significant relaxation occurring at the two highest doses of MRE-269 of 10 and 100 μM.
|
分子结构图
